Analytical Data
-
基因名
CT45A1
- Application
-
种属
Human
-
表达系统
E. coli
-
标签
N-His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q5HYN5
-
表达区间
Met1~Ile189
-
分子量
27kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CT45A1, a member of the Cancer/Testis Antigen (CTA) family, has garnered significant attention in cancer research due to its restricted expression profile. Unlike many antigens that are broadly expressed in healthy tissues, CT45A1 is predominantly found in testicular germ cells and various cancer types, particularly melanoma, bladder cancer, and certain types of leukemia. This selective expression pattern makes CT45A1 an appealing target for cancer immunotherapy, as it may elicit an immune response with minimal off-target effects. Recent studies suggest that the presence of CT45A1 can be correlated with tumor progression and patient prognosis, indicating its potential role as a biomarkers. Additionally, the development of CT45A1-based vaccines and adoptive T-cell therapies is being explored, aiming to harness the immune system to specifically target and eliminate cancer cells expressing this antigen. Overall, the research on CT45A1 not only enhances the understanding of tumor immunology but also paves the way for innovative therapeutic strategies in cancer treatment.
